PRLD Earnings

PRLD reported its FY2025Q3 earnings on 2025-11-12, showcasing a revenue of 6.50M against an estimate of , resulting in a 0% surprise. The EPS was -0.26, surpassing the expected -0.35 by 25.71%. The stock experienced a 8.89% price change on the earnings day and a 22.22% change over the next five days, reflecting market reactions to the results.

Following PRLD's FY2025Q3 earnings announcement on 2025-11-12, the stock price moved by 8.89% on the day of the release. Over the subsequent five days, it saw a 22.22% change. Historically, PRLD's stock price tends to shift by an average of 7.23% in the 10 days leading up to earnings and 17.12% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate PRLD's annual revenue to reach 20.50M, while the EPS is projected at -0.28. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between PRLD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PRLD's stock price typically moves by 7.23% in the 10 days before its earnings and 17.12% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.28 and revenue of 20.50M.

The earnings call reveals a mixed outlook. Financially, the $60 million from Incyte is positive, but the lack of clear guidance and competitive pressures in the oncology market are concerning. The strategic partnership with Incyte and robust preclinical models are positive, but significant regulatory and execution risks remain. The Q&A highlighted competitive pressures and uncertainties in timelines, suggesting a cautious market response. Overall, the sentiment is balanced, leading to a neutral prediction for stock movement.